Preventing the Next Fertility Clinic Scandal
By Jesse Reynolds,
Bioethics Forum
| 03. 13. 2009
Given the U.S. fertility industry's longstanding resistance to effective oversight, the field's two recent controversies - first octuplets, then an offer of embryo screening for cosmetic traits - shouldn't really come as a surprise. What was remarkable about the reaction they evoked from knowledgeable observers, in fact, was the chorus of agreement that it's time to leave the "Wild West" days of assisted reproduction behind.
The octuplets story turned many of us into reluctant voyeurs, fascinated by the daily dribble of details. Fortunately, at least some of the media attention soon turned away from the unsettling details about the babies' mother and focused instead on the fertility doctor involved. We soon learned that Michael Kamrava had not only transferred six embryos - two of which divided into twins - into the octuplets' mother, but had also recently put seven embryos into another woman who wanted only one child, leaving her pregnant with quadruplets.
The industry that had tolerated such irresponsible medical conduct also came under much-needed scrutiny. Many people were surprised to learn that the multibillion dollar American fertility industry...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...